TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Electrical impedance difference between surgical margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Whole body effective dosimetry measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DICE similarity coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contouring time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in esophagus outer diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Rate of correct visualisation during debulking surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants with Incidence of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Depressive Symptoms Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Mobility scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of pain medication used after surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: primary stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stability at the dip period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: secondary stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of total body weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paternal mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posterior mandibular ridge resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcomes Score (KOOS-12)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Smile arc assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tricuspid regurgitation volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of GVHD at one year post-transplant
Endpoint domain: Adverse events/effects
Primary endpoint: Graft rejection at one year post-transplant
Endpoint domain: Adverse events/effects
Primary endpoint: Participation rate at healthy life-centers
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Use of smoking cessation aids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline Dialysis Symptom Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Musculoskeletal, Power Doppler Ultrasound (MSK-PDUS) Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Patients Transitioning to Psoriatic Arthritis (PsA) by Modified CASPAR Criteria at Year 2
Endpoint domain: Mortality/survival
Primary endpoint: Cure rate at day 15
Endpoint domain: Mortality/survival
Primary endpoint: catheter placement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnosis of Parkinson's disease dementia (PDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level II diagnosis of mild cognitive impairment in Parkinson's disease (PD-MCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fear-avoidance belief changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment adherence- self-report
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment adherence- pill count
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment adherence- electronic monitoring device (EMD)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Early treatment discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knowledge Level of Thorax and Lung Physical Examination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Skill Level in Thorax and Lung Physical Examination
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Immediate pre-operative anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Unanticipated Adverse Device Effects (UADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Hydrogen peroxide level in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLNO/DLCO-ratio repeatability coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: DLCO repeatability coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: DLNO repeatability coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in motor development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative complete healing rate for ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in serum levels of TNF-α and IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Insula Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on inflammatory C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Remission of hyperthyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adverse effects of methimazole
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with a complete four-nerve sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Incisional Hernia at ultrasonographic examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of patients undergoing first screening scan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in pCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bilirubin level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acceptability in real conditions of use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in portal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occurrence of symptoms after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: General Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disease-Related Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Time device was worn
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Subjects with Point 7 or Point 8 in the 8 point ordinal scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale Part Ⅲ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement (risk profile)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Atrial Fibrillation, Atrial Tachycardia and Atrial Flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evaluation of major adverse events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Non-compliance with hydroxychloroquine treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants without Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Change in Tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relative Change in Tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Participants Who Responded to Treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reason for dropout
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement changes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the concentration-time curve from time zero to the last quantifiable concentration (t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Score of Knowledge, Attitudes, and Intentions Towards Organ Donation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Analog Scale for Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short General Comfort Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of frailty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of neuro-psychomotor developmental disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mutation test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin thermometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral tissue oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nursing safety precautions effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of hospitalisation for acute heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adequate gas exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adequate flow to the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, frequency, and seriousness of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: ORR based on radiological assessment according to the RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Agreement of drug concentrations of antivirals and relevant metabolites/anabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with Serious AEs, AEs Leading to Discontinuation of Study Vaccine or Withdrawal From the Study, and AEs of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Medically Attended AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of Cortisol in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Outcome Measures in Arterial pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Outcome Measures in Heart rate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change Psychological stress measurement scale levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percentage of patients with a good outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: oscillation about the X-axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oscillation about the Y-axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area of the ellipse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urethral patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGM-measured percent time in range 70-180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Trial Team Members Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Demand
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Practicality
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Risk of progression to symptomatic cancer
Endpoint domain: Mortality/survival
Primary endpoint: Change in aortic and brachial systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in carotid-femoral pulse wave velocity (cfPWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biomarker performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Yale Preoperative Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the ROC Curve (AU ROC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of successful calls
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percent receiving COVID-19 Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immune response to COVID-19 vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Thickness of Thigh Muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Size of the ischemic focus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Inflammatory Hyperpigmentation Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mitochondria function measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in minimal erythema dose (MED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reliability of the C-CLDEQ-8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in carbohydrate intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average 24-hour glucose total area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low 5 minute Apgar score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Emotional Distress (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Post-traumatic Stress (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Quality of Life (EQ-5D-3L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: LARS Score with Night symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health-Related Quality of Life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of refractive error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rhinosinusitis symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence and number of DLT
Endpoint domain: Adverse events/effects
Primary endpoint: AE, SAE occurrence and frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Safety evaluation of YOLT-101
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in pain score, age 3-7 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain score, age 8-18 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline muscle volume at 9 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline dynamic muscle strength at 9 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle fiber type specific hypertrophy at 9 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-SARS-CoV-2 neutralising immunoglobulin titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Donor resumption of brain blood flow and/or activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Diagnostic Interview Status (CDRS-R) total score from baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Adolescent Longitudinal Interval Follow-Up Evaluation (A-LIFE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of adverse effects after prime-boost vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Titers of anti-SARS-CoV-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with abnormal clinical laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with abnormal ECG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with abnormal physical exams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with abnormal spirometry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Scapular stabilizing muscles strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Quarter Y Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beverage Calories Purchased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Beverage Added Sugars Purchased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Live ventilator-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Surgical successful rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Score in oral language tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: User Adherence Meta-Variables
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in attention switching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sociomoral attention switching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cue reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coding percentage of use per night
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: percentage of nights used for the duration of the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: self-report satisfaction survey, Was It Worth It questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spread of extended spectrum beta lactamase producing gram negative bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Metaphase-II oocytes rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rustogi Modified Navy Plaque Index (RMNPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Joint Repositioning Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of bone healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ivermectin drug exposure - Area under the concentration-time curve (AUC0- ∞ )
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Test Scores on Knowledge about Hepatitis B-C
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Opioid Withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological Clearance of treated isSCC lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: suPAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical chemistry examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematology examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinalysis changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain in target knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety Follow-up Period outcomes
Endpoint domain: Adverse events/effects